Tong Ren Tang Technologies Co. Ltd. Receives Key Macau Medicine Registration

Key Highlights

• Certificate of Registration Awarded: Tong Ren Tang Technologies Co. Ltd. (“TRT Technologies” or the “Company”) has announced that its subsidiary, Beijing Tong Ren Tang (Macau) Company Limited (“TRT Macau”), has received the Certificate of Registration of Proprietary Chinese Medicine from the Pharmaceutical Administration Bureau of the Macao Special Administrative Region Government.
• Product Approved for Sale in Macau: The approved product, “Jin Chai Shi Hu San【Tong Ren Tang】” (金釵石斛散【同仁堂】), can now be legally sold in the Macau market.
• Potential Market Expansion: This development allows the Group to expand its market presence within Macau, potentially opening up new revenue streams.
• Investment in R&D: The Group has invested approximately HK\$2 million (unaudited) in the research and development of “Jin Chai Shi Hu San【Tong Ren Tang】”.
• Product Indications: The medicine is indicated for a range of conditions, such as heat disease consuming fluid, dry mouth, vexation and thirst, stomach yin deficiency, reduced food intake, retching, deficiency heat after recovery from illness, yin deficiency with effulgent fire, steaming bone and consumptive fever, dim and blurred vision, and limp, weak sinew and bone.

Details for Investors and Shareholders

The issuance of the Certificate of Registration is a significant regulatory milestone that authorizes the sale of “Jin Chai Shi Hu San【Tong Ren Tang】” in the Macau Special Administrative Region. This achievement demonstrates the Company’s ongoing commitment to expanding its portfolio of proprietary Chinese medicines and entering new markets.

Impact on the Company: While this announcement is positive for the Group’s long-term growth strategy and market expansion, management has stated that the registration itself will not have a material impact on the Company’s production, operation, or financial performance in the near term. However, the ability to sell in Macau represents an important step for future revenue growth and brand recognition in the region.

Potential Price Sensitivity

• Market Expansion Potential: The approval enhances TRT Technologies’ potential to penetrate the Macau pharmaceutical market, which may be viewed positively by investors anticipating future revenue growth.
• Regulatory Risk: The Company notes that sales of pharmaceutical products in Macau may be affected by changes in policy, exchange rate fluctuations, and market competition. These risks should be considered by shareholders.
• Investment Disclosure: The R&D investment of approximately HK\$2 million signals ongoing commitment to product innovation and expansion, though it is not expected to immediately affect earnings.

Corporate Governance Update

As of the announcement date, the Board of Tong Ren Tang Technologies Co. Ltd. comprises a mix of executive, non-executive, and independent non-executive Directors, chaired by Mr. Zhang Yi.

Conclusion

In summary, the registration of “Jin Chai Shi Hu San【Tong Ren Tang】” for sale in Macau is a strategic development for Tong Ren Tang Technologies Co. Ltd. While short-term financial impact may be limited, the long-term potential for market expansion and new revenue streams could influence investor sentiment. Shareholders and potential investors are advised to monitor future updates and exercise caution in their investment decisions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The sale and performance of pharmaceutical products are subject to regulatory, market, and economic risks. Investors should conduct their own research and consult with professional advisors before making investment decisions.

View TONG REN TANG Historical chart here